Many venture industry observers have wondered whether Andreessen Horowitz, a firm that manages $45 billion, has its sights on ...

In the fireside chat, Dr. Rhew described how AI-driven modeling and simulation are drastically reducing the time required to identify and develop drug candidates. He provided an example where a ...

JPM25: Amid Samsung Bio's rapid expansion ... Amid all the dealmaking chatter at this week's J.P. Morgan Healthcare Conference, China was a frequent topic of conversation. At Roche, the company ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech dev ...

We recently published a list of 10 Best Mid-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Year-over-year BioSpace data shows there were fewer job postings live on the website in the fourth quarter of 2024, and the ...

Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will ...

ABL Bio, which is developing new drugs based on a dual antibody ... Lee said, “During a meeting held during the JP Morgan Healthcare Conference (JPM 2025) this month, global big pharmaceutical ...

Belle da Costa Greene, who was JP Morgan’s librarian, became a lively fixture at Gilded Age mansions, country retreats, ...

With another JP Morgan in the rearview mirror ... Andrew Obershain, CEO of bluebird bio, said as much on stage. A year before the FDA approved his company’s gene therapy for sickle cell ...